Question · Q4 2025
Zhihong Chen questioned BeOne Medicines' strategy for its emerging immunology pipeline, seeking elaboration on the path to becoming a significant player beyond hematology and solid tumors.
Answer
Lai Wang, President and Global Head of R&D, explained that approximately 20% of the preclinical pipeline focuses on immunology, with a goal to identify 1-2 cornerstone assets within 2-3 years, some of which are already in clinical stages.
Ask follow-up questions
Fintool can predict 
ONC's earnings beat/miss a week before the call